Viral Triggers in Hemophagocytic Lymphohistiocytosis (HLH)

Introduction to Viral HLH

• The American Society of Hematology recommends that treatment decisions for HLH should never be delayed while awaiting viral test results, as mortality ranges from 20-88% without prompt treatment 1
• Viral infections, particularly EBV, CMV, HIV, and influenza, are the most common triggers of secondary HLH in adults, accounting for the majority of infection-associated cases 2

Distinguishing True Viral Triggers

• EBV DNA levels >10³ copies per milliliter are clinically relevant for the development of EBV-HLH, helping distinguish true triggers from incidental detection 2, 3
• The European Society for Medical Oncology suggests that serial monitoring of ferritin, soluble CD25, cell counts, and viral DNA levels (for EBV/CMV) guides treatment decisions 2, 3

Treatment Algorithm

• The American College of Physicians recommends initiating virus-specific treatment immediately (antivirals for CMV/influenza) for all patients with confirmed viral HLH 2, 3
• The National Comprehensive Cancer Network suggests starting corticosteroids (dexamethasone 5-10 mg/m² or prednisolone 1-2 mg/kg) in all cases of viral HLH 3

Critical Pitfalls to Avoid

• The American Society of Hematology advises that the clinical decision to treat HLH should never be delayed pending viral test results or genetic testing 1
• 40-70% of adult HLH cases are malignancy-associated, with lymphoma being the most common underlying trigger, according to the European Hematology Association 5, 1
• The Infectious Diseases Society of America recommends using PET-guided imaging, repetitive tissue sampling, and consultation with lymphoma reference pathologists when HLH etiology remains unclear 5, 1

Recognizing Pathogens Requiring Specific Treatment

• The Centers for Disease Control and Prevention suggests that patients with pathogens targeting the monocyte-macrophage system (Leishmania, Rickettsia, tuberculosis, malaria) should receive specific antimicrobial treatment rather than immunosuppression 2, 4
• The World Health Organization recommends that these patients typically respond well to pathogen-directed therapy without requiring full HLH-94 protocols 2, 4